Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress
Decision brief
Answer first · skim in under a minute
Idorsia's investigational vaccine, IDOR-1134-2831, targeting Clostridioides difficile infection (C. diff), has demonstrated continued positive clinical trajectory in early-stage trials. The vaccine aims to prevent recurrent C. diff infections, a significant unmet medical need.
Idorsia reported additional Phase 1 results on June 1, 2026 for IDOR-1134-2831, its synthetic glycan vaccine against Clostridioides difficile. High-dose cohorts showed dose-dependent IgG immunogenicity with acceptable tolerability; the program remains early-stage, not a Phase 3 efficacy read.
Contents9 sections
Key Takeaways
- June 1, 2026 GlobeNewswire: high-dose IDOR-1134-2831 was safe, well-tolerated, and immunogenic in all high-dose healthy participants.
- Phase 1 design: double-blind, randomized, placebo-controlled, up to four ascending doses in adults aged 18–49 years.
- Idorsia cites almost 400,000 U.S. C. difficile infections yearly and more than 25,000 U.S. deaths; recurrence after treatment can reach about 25%.
- NCT03090191 is Pfizer’s completed Phase 3 CLOVER trial—not an Idorsia study; that misattribution is corrected here.
What Data Did Idorsia Report for IDOR-1134-2831?
According to Idorsia’s June 1, 2026 GlobeNewswire release, IDOR-1134-2831 targets a glycan present on both C. difficile bacteria and spores of clinically relevant strains, including hypervirulent variants. After June 2025 initial Phase 1 validation, the company advanced a higher-dose cohort.
Results in healthy high-dose participants confirmed safety and tolerability, a dose-dependent IgG response, and immunogenicity in all high-dose participants. Exploratory tests highlighted dose-dependent IgG1 responses linked to opsonization.
What Is the Phase 1 Trial Design?
Idorsia describes a double-blind, randomized, placebo-controlled, two-part clinical pharmacology trial assessing safety, tolerability, and immunogenicity across up to four ascending dose levels in healthy participants aged 18 to 49 years. The company positions the candidate for prevention of CDI in hospital and community risk groups and says it intends to advance via partnership.
Why Does the Field Still Lack an Approved C. diff Vaccine?
Idorsia’s release notes C. difficile as a leading cause of antibiotic-associated diarrhea, with almost 400,000 U.S. infections yearly and more than 25,000 U.S. deaths, plus recurrence in up to 25% of treated patients. Broader antimicrobial-resistance context is summarized by the WHO antimicrobial resistance fact sheet.
Prior toxoid approaches struggled late-stage. ClinicalTrials.gov NCT03090191 is Pfizer’s completed Phase 3 Clostridium Difficile Vaccine Efficacy Trial (CLOVER)—a useful competitive benchmark, not Idorsia’s registration.
What Remains Unproven?
Phase 1 immunogenicity in healthy adults does not prove prevention of CDI in older or antibiotic-exposed patients. No efficacy endpoint, pivotal design, or approval timeline is established in the June 2026 release. Partnering intent is stated; a signed commercialization partnership is not.
What Should Investors Watch Next?
Watch full Phase 1 presentation details, dose selection for later studies, partnership announcements, and any new ClinicalTrials.gov registration that actually lists Idorsia as sponsor for an efficacy trial. Do not treat Pfizer’s NCT03090191 as an Idorsia catalyst.
Related NovaPharma coverage
- OS Therapies OST-HER2 osteosarcoma articles
- EU clinical trial recruitment informed consent template
- Clostridioides difficile infection hub
Frequently Asked Questions
What is IDOR-1134-2831?
IDOR-1134-2831 is Idorsia’s investigational synthetic glycan vaccine for prevention of Clostridioides difficile infection. The company says the glycan target is present on both bacteria and spores of clinically relevant strains, including hypervirulent variants.
What Phase 1 results did Idorsia report on June 1, 2026?
In a GlobeNewswire release dated June 1, 2026, Idorsia said high-dose healthy participants showed the vaccine was safe and well-tolerated, with a dose-dependent IgG response and immunogenicity in all high-dose participants in the Phase 1 clinical pharmacology trial.
Is NCT03090191 Idorsia’s trial?
No. ClinicalTrials.gov lists NCT03090191 as Pfizer’s completed Phase 3 Clostridium Difficile Vaccine Efficacy Trial (CLOVER). Idorsia’s June 2026 update describes its own Phase 1 program for IDOR-1134-2831 and does not identify that Pfizer registration as an Idorsia study.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for IDOR-1134-2831.
Unlock full calendar →This article follows our editorial standards. Report a correction via editorial contact.
